Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **Bone morphogenetic protein 9 (BMP‑9) receptor complex** refers to the multi-protein assembly that mediates cellular responses to BMP‑9, a member of the transforming growth factor beta (TGF‑β) superfamily. BMP‑9, also known as growth and differentiation factor 2 (GDF2), is a cytokine with diverse biological roles including potent induction of osteogenesis and chondrogenesis, regulation of glucose metabolism, neuronal differentiation, fibrosis modulation, and lymphatic development[1][3]. The canonical signaling occurs through binding to specific serine/threonine kinase receptors on the cell surface. The primary high-affinity type I receptor for BMP‑9 is **activin receptor-like kinase 1** (**ALK1**, also called ACVRL1), which forms a heteromeric signaling complex with type II receptors such as BMPR-II or ActRIIA/IIB upon ligand binding[1]. This triggers downstream SMAD-dependent transcriptional programs. The term "Bone morphogenetic protein 9 receptor complex" is not itself a single molecule but rather describes this functional assembly; thus it may be considered an imprecise or non-canonical target name. The individual components—such as ALK1—are established therapeutic targets in vascular diseases and cancer research. BMP‑9 has been shown to protect against myocardial infarction by improving lymphatic drainage function and enhancing mitochondrial bioenergetics in cardiac tissue via upregulation of DECR1 expression; deficiency in either BMP‑9 or DECR1 exacerbates cardiac injury after MI in animal models[3]. No approved drugs are currently known to directly target the entire "BMP‑9 receptor complex," though modulators of TGF-beta family signaling are under investigation for related pathways. Because "Bone morphogenetic protein 9 receptor complex" does not refer to a single gene product or standardized drug target but rather an assembly involved in signal transduction for BMP‑9/GDF2 ligands via ALK family receptors, this entry should be flagged as potentially incorrect or too broad for structured database use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bone morphogenetic protein 9 receptor complex.